Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism ; volume:14 ; number:1 ; day:4 ; month:4 ; year:2014 ; pages:1-7 ; date:12.2014
BMC cancer ; 14, Heft 1 (4.4.2014), 1-7, 12.2014
- Creator
-
Schoellhammer, Hans F.
- Contributor
-
Hsu, Felicia
Vito, Courtney
Chu, Peiguo
Park, Jinha
Waisman, James
Kim, Joseph
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-14-242
- URN
-
urn:nbn:de:1111-2016030418414
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schoellhammer, Hans F.
- Hsu, Felicia
- Vito, Courtney
- Chu, Peiguo
- Park, Jinha
- Waisman, James
- Kim, Joseph
- SpringerLink (Online service)
Other Objects (12)
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Appendicitis caused by the metastasis of HER2-positive breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Appendicitis caused by the metastasis of HER2-positive breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Appendicitis caused by the metastasis of HER2-positive breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer